Citi Keeps Their Buy Rating on Allogene Therapeutics (ALLO)
Citi analyst Samantha Semenkow reiterated a Buy rating on Allogene Therapeutics (ALLO – Research Report) yesterday and set a price target of $4.00.
Confident Investing Starts Here:
According to TipRanks, Semenkow is an analyst with an average return of -20.6% and a 26.32% success rate. Semenkow covers the Healthcare sector, focusing on stocks such as Argenx Se, Allogene Therapeutics, and Catalyst Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Allogene Therapeutics with a $8.33 average price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Ulta Beauty Stock (ULTA) Maintains Bold Comeback Following Q1 Beat
After a rocky couple of years, Ulta Beauty (ULTA) is staging a fierce comeback, with its stock surging and its investment case looking increasingly better by the quarter. Evidently, the company's Q1 results posted just last week lit a spark under the stock, showcasing robust comparable sales growth, strategic wins, and an aggressive share buyback program. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Despite its recent rally, I believe Ulta Beauty still offers attractive value, making it a compelling choice for long-term investors. Here's why I remain bullish on the stock. Walking into an Ulta store these days feels like stepping into a bustling beauty bazaar, and the numbers certainly back up that vibe. In Q1, Ulta reported a 2.9% increase in comparable sales, blowing past Wall Street's modest expectations of just 0.2% growth. This uptick, driven by a 2.3% rise in average ticket size and a 0.6% increase in transactions, shows Ulta is pulling customers back in a big way, even in the face of the brutal competition facing the beauty industry these days. Under new CEO Kecia Steelman, the company's 'Ulta Beauty Unleashed' plan is resonating, with fresh promotions and a beefed-up loyalty program, now boasting a record 44.6 million members and keeping shoppers hooked. One could argue that this is a one-quarter fluke. However, Ulta's focus on exclusive products and in-store experiences, like their expanded Target shop-in-shops, is undeniably driving traffic. There is no reason to think that this trend will fade soon, especially since Ulta is coming off some difficult quarters (hence the stock's underperformance in 2024), and the recent numbers indicate that a proper rebound has now been established. To be frank, the company's ability to outpace estimates in such a tough retail environment (particularly competition-wise) signals a consumer base that's still willing to splurge on beauty, even during a period of economic uncertainty. One of the more interesting takeaways from Ulta's report is that the company isn't solely relying on its core business to drive growth, but is instead exploring new opportunities. During the earnings call, executives talked about plans to expand into Mexico and the Middle East this year. They've already opened six new stores this quarter, bringing their total to 1,451, after adding 100 Ulta Beauty stores at Target locations last year. Interestingly, these moves don't necessarily seem to be about expanding square footage (as is the case with retailers), but rather about making Ulta a go-to destination for beauty lovers everywhere. Then there's the loyalty program, which grew 3% last year to the 44.6 million mark. It's a sticky ecosystem that keeps customers coming back, and Ulta is doubling down with digital upgrades and personalized marketing. When you pair these efforts with exclusive brand launches, you can see how Ulta can claw back market share from competitors like Sephora and Amazon, even as those giants loom large. Ulta has a tremendous track record of share repurchases. It has essentially been using the majority of its free cash flow over the years to repurchase as many shares as possible. For context, over the past decade, Ulta has reduced its share count by 30%. In Q1, this trend endured, with Ulta repurchasing $249.5 million worth of stock. With $2.7 billion still available under their $3 billion program, Ulta is signaling confidence in its future and the stock's present valuation. I love seeing a company bet on itself like this. Management is like they're saying, 'We know we're undervalued, and we're not afraid to prove it.' Regarding Ulta's valuation, even after the stock's post-earnings rebound, it's still trading at just 20x this year's expected EPS. Considering that sales are on the rebound, margins are stabilizing, and buybacks are continually reducing the share count, EPS growth is expected to pick up in the coming years. In fact, repurchasing shares at today's valuation is likely to prove exceptionally accretive in the long term. Therefore, I believe that the current multiple undervalues Ulta's medium-term prospects. Despite the stock's recent rebound, Wall Street remains optimistic about Ulta. The stock still features a Moderate Buy consensus rating, with 12 analysts currently bullish, 12 neutral, and just one bearish. Now, Ulta's average stock forecast of $470.04 indicates marginal downside potential over the coming twelve months. Ulta Beauty appears to be regaining its momentum. The company delivered strong comparable sales, executed key strategic initiatives, and continues to return value to shareholders through a robust buyback program. Trading at roughly 20 times earnings, Ulta offers a compelling blend of value and growth—an uncommon combination in the often-volatile retail sector. With a meaningful margin of safety and solid upside potential, the stock presents a highly attractive investment opportunity at current levels. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
NeuroPace Secures Up to $75 Million in Debt Financing
MOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company has entered into a new $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit facility. Proceeds from the new term loan were used to fully repay NeuroPace's term loan with CRG Partners IV, L.P., with proceeds of the new revolving credit facility available for working capital needs and other corporate purposes. 'We are pleased to partner with MidCap Financial on this new credit facility, which provides non-dilutive capital at favorable terms that reduce our cash interest expense and support the continued growth of our business,' said Joel Becker, Chief Executive Officer of NeuroPace. 'The proceeds and improved structure provide us the financial strength and flexibility to continue expanding patient access to the RNS® System and to invest in key growth initiatives, including site-of-service expansion, new indications, direct-to-consumer programs, new product development and real-world evidence generation. We also want to thank CRG for their partnership and support over the past several years. They have been an excellent partner in the Company's development.' The Company's new loan agreement includes a maturity date of five years for both the term loan and revolving credit facility. The annual interest rate is equal to SOFR subject to a floor of 2%, plus (1) 5.5% under the term loan and (2) 3.75% under the revolving loan. Armentum Partners served as financial advisor to NeuroPace on the transaction. Additional detail regarding the foregoing financing is set forth in NeuroPace's Current Report on Form 8-K, filed today with the U.S. Securities and Exchange Commission. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. About MidCap Financial MidCap Financial is a middle-market focused, specialty finance firm that provides senior debt solutions to companies across all industries. As of March 31, 2025, MidCap Financial provides administrative or other services for approximately $55 billion of commitments*. MidCap Financial is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, Inc., pursuant to an investment management agreement. Apollo had assets under management of approximately $785 billion as of March 31, 2025, in credit, private equity and real assets funds. For more information about MidCap Financial, please visit For more information about Apollo, please visit *Including commitments managed by MidCap Financial Services Capital Management LLC, a registered investment adviser, as reported under Item 5.F on Part 1 of its Form ADV Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding: NeuroPace's expectations, forecasts and beliefs regarding the use of proceeds from the term loan and revolving credit facility with MidCap Financial. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including those described more fully in the section titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in NeuroPace's public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 13, 2025, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace's views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace. Investor Contact:Scott SchaperHead of Investor Relationssschaper@
Yahoo
5 hours ago
- Yahoo
TSMC Defies Gruesome Geopolitical Odds With Friends in High Places
As an avid follower of semiconductor stocks, I'm genuinely excited by the recent momentum in Taiwan Semiconductor Manufacturing Company (TSM), widely known as TSMC. The stock has decisively broken above its key 50-week moving average—a technical milestone that's hard to overlook. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter However, my optimism extends far beyond chart patterns. TSMC is a pivotal force at the heart of the AI revolution, playing a crucial role in powering next-generation technologies. The company is aggressively expanding its global footprint with major facilities planned across Europe, the U.S., and most intriguingly, the United Arab Emirates. For investors who recognize the strategic significance of technological leadership, TSMC is far more than just another chipmaker—it's a cornerstone of global economic and national security. Given the confluence of positive factors surrounding TSMC stock, I'm confidently bullish on its chances of picking its way through the brewing geopolitical minefield to, ultimately, deliver strong shareholder returns for the next decade. From a financial standpoint, TSMC's performance in Fiscal 2025 has been nothing short of exceptional. In the first quarter alone, revenue surged by 35% year-over-year, reaching approximately $25.5 billion. This impressive growth has been fueled by strong and timely demand from high-performance computing and automotive sectors, more than offsetting temporary softness in the smartphone market. Notably, TSMC's cutting-edge 3-nanometer process has become a meaningful contributor to revenue, further underscoring the company's leadership in advanced semiconductor manufacturing. Despite facing some operational headwinds, including an early-year earthquake, TSMC has maintained robust profitability. Non-GAAP gross margins came in at around 59%, significantly beating analysts' subdued expectations. Management also remains highly optimistic about the near-term outlook, guiding for another strong quarter with an anticipated 38% year-over-year revenue increase in Q2. Altogether, this powerful blend of rapid growth and resilient profitability signals that TSMC is far more than a cyclical beneficiary. It is a foundational force in the global tech ecosystem, building lasting competitive moats and firmly establishing itself as the dominant player in semiconductor manufacturing. I've taken a deep interest in TSMC's bold and rapidly unfolding global expansion strategy. The company's landmark $100 billion investment in Arizona represents more than just a manufacturing footprint—it signals a decisive pivot by the U.S. toward strengthening domestic semiconductor resilience. While challenges such as elevated labor costs and project delays are to be expected, the long-term strategic value is substantial. This initiative cements TSMC as a foundational technology partner for the West and a central pillar of the emerging U.S. semiconductor ecosystem. Equally impressive is TSMC's growing presence in Europe. Its joint venture in Dresden, Germany—alongside Bosch, Infineon (IFNNY), and NXP Semiconductors (NXPI)—marks a transformative effort to reshape the continent's semiconductor supply chain. With a total project cost of approximately €10 billion, half of which is backed by EU state aid, the partnership aims to reduce Europe's reliance on external sources for advanced chips. This move is not only strategically sound but also enhances TSMC's global resilience and influence. Perhaps the most intriguing development is the proposed 'gigafab' in the United Arab Emirates. TSMC is reportedly in discussions with Abu Dhabi's sovereign wealth fund, Mubadala, which, if finalized, would signal a breakthrough expansion into the rapidly evolving tech ambitions of the Middle East. Though still speculative, this potential partnership could significantly extend TSMC's geopolitical reach and strategic footprint. Altogether, TSMC's global initiatives reflect a visionary approach to navigating complex geopolitical and economic terrains. These moves aren't just about scaling production—they're about redefining the global semiconductor map, securing long-term relevance, and reinforcing TSMC's status as a trailblazer in advanced manufacturing. Technically speaking, TSMC's recent price action represents an undeniably eye-popping bull pattern, drawing tremendous interest from institutional investors. The technical indicators, such as the Relative Strength Index, down in the mid-60s, suggest that TSMC has plenty of room for continued gains before becoming overbought. In fact, even heavyweights such as Cathie Wood's ARK Invest have recently increased their holdings in TSMC. This adds another dimension of institutional confidence that deserves the attention of retail investors. For me, the institutional dynamics tell a strong story about why TSMC will continue to compound returns impressively. That said, while I remain optimistic about TSMC's long-term prospects, the geopolitical risk surrounding China and Taiwan is both real and significant. The increasing military activity by China's People's Liberation Army in the Taiwan Strait cannot be overlooked. According to various intelligence reports, China is preparing for potential scenarios involving Taiwan, with a key timeline centered around 2027. Should a military conflict occur, the consequences for TSMC would be severe. Its critical manufacturing facilities could face operational disruptions or even destruction, triggering a major shock to the global semiconductor supply chain. Based on my analysis, such an event could lead to a collapse in TSMC's stock price, potentially as much as 60%. Given the scale of this risk, it demands careful consideration. Even with a fundamentally bullish outlook, I believe it's essential to have a clear risk-management strategy in place. This is not about fear—it's about being realistic in the face of a complex and evolving geopolitical landscape. On Wall Street, TSMC stock holds a consensus Strong Buy rating, supported by seven Buy ratings, one Hold, and zero Sells. TSMC's average stock price target sits at $219.43, suggesting a potential upside of 13% over the next 12 months. Personally, I'm a bit more bullish, with my own price target closer to $250. Overall, I remain firmly bullish on TSMC. This investment goes beyond financials—TSMC is a cornerstone of the global technology infrastructure. While the geopolitical risk tied to its location in Taiwan is both real and substantial, it's a factor that strategic investors must weigh carefully. For those capable of evaluating the balance between opportunity and geopolitical exposure, TSMC presents a rare and compelling proposition. Given the company's dominant market position and long-term growth potential, my $250 price target feels not only reasonable but well within reach. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
